Side by side
IGF-1 LR3 vs MK-677
Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| IGF-1 LR3 | MK-677 | |
|---|---|---|
| What it is | A modified insulin-like growth factor engineered to last far longer in the body than the natural hormone. It can cause hypoglycaemia, which makes it the most acutely dangerous compound on this site. | An orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Not a peptide, and not injected. It is a small molecule taken by mouth. |
| EvidenceHow much human evidence exists, not how well it works. | Preclinical | Early human trials |
| Regulatory statusReviewed 2026-08-16 | Not approved for human use in any jurisdiction, and never studied in a human trial. Recombinant IGF-1 itself (mecasermin) is approved for severe primary IGF-1 deficiency, and its labelling carries an explicit hypoglycaemia warning. That warning is the closest thing to clinical safety information this class has. | Not approved for human use in any jurisdiction. Development was not completed. It is widely sold as a 'research chemical' or mislabelled as a dietary supplement, which it is not. It is an unapproved drug. |
| Routes | Subcutaneous, Intramuscular | Oral |
| Half-life | 24 hours | 24 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $32.50/mg | $0.64/mg |
| Median per mg | $79.00/mg | $2.94/mg |
| Vendors with a price | 32 | 6 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. Larger proteins are less forgiving of temperature swings than short peptides. | Not applicable. Liquid preparations sold in solution should follow the seller's storage instructions, which is a weaker guarantee than it sounds. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.